{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T05:59:59Z","timestamp":1719208799024},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,18]]},"DOI":"10.7759\/cureus.16460","type":"journal-article","created":{"date-parts":[[2021,7,18]],"date-time":"2021-07-18T16:20:01Z","timestamp":1626625201000},"source":"Crossref","is-referenced-by-count":1,"title":["Plausible Role of Asthma Biological Modifiers in the Treatment of Eosinophilic Esophagitis"],"prefix":"10.7759","author":[{"given":"Timothy  C","family":"Olsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A","family":"Promisloff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"DeCostanzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony M","family":"Szema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(77)80034-6","article-title":"Eosinophilic gastroenteritis with esophageal involvement","volume":"72","author":"Dobbins JW","year":"1977","unstructured":"Dobbins JW, Sheahan DG, Behar J. Eosinophilic gastroenteritis with esophageal involvement. Gastroenterology. 1977, 72:1312-1316. 10.1016\/S0016-5085(77)80034-6","journal-title":"Gastroenterology"},{"key":"ref2","unstructured":"Digestive diseases. Mayo Clinic, Mayo Foundation for Medical Education and Research. (2017). http.\/\/www.mayoclinic.org\/medical-professionals\/digestive116 diseases\/news\/use-of-dietary-strategies-in-treating-eoe\/...."},{"key":"ref3","doi-asserted-by":"crossref","DOI":"10.1177\/1941874412458678","article-title":"Glucocorticoids: complications to anticipate and prevent","volume":"3","author":"Gensler LS","year":"2013","unstructured":"Gensler LS. Glucocorticoids: complications to anticipate and prevent. Neurohospitalist. 2013, 3:92-97.","journal-title":"Neurohospitalist"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2015.399","article-title":"Outcomes of esophageal dilation in eosinophilic esophagitis: safety, efficacy, and persistence of the fibrostenotic phenotype","volume":"111","author":"Runge TM","year":"2016","unstructured":"Runge TM, Eluri S, Cotton CC, Burk CM, Woosley JT, Shaheen NJ, Dellon ES. Outcomes of esophageal dilation in eosinophilic esophagitis: safety, efficacy, and persistence of the fibrostenotic phenotype. Am J Gastroenterol. 2016, 111:206-213. 10.1038\/ajg.2015.399","journal-title":"Am J Gastroenterol"},{"key":"ref5","unstructured":"American Partnership for Eosinophilic Disorders (APFED). EoE. (2021). https.\/\/apfed.org\/about-ead\/egids\/eoe\/."},{"key":"ref6","unstructured":"Eosinophilic esophagitis. developing drugs for treatment guidance for industry. (2020). Accessed: June 30, 2021: https:\/\/www.fda.gov\/media\/120089\/download."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-012615-044241","article-title":"Mechanisms of disease of eosinophilic esophagitis","volume":"11","author":"Davis BP","year":"2016","unstructured":"Davis BP, Rothenberg ME. Mechanisms of disease of eosinophilic esophagitis. Annu Rev Pathol. 2016, 11:365-393. 10.1146\/annurev-pathol-012615-044241","journal-title":"Annu Rev Pathol"},{"key":"ref8","unstructured":"Federal Drug Administration. (n.d.). FASENRA (benralizumab) - US Food and Drug Administration. Accessdata.FDA.gov. https.\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761070s000lbl.pdf."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/1753465816667659","article-title":"The clinical profile of benralizumab in the management of severe eosinophilic asthma","volume":"10","author":"Menzella F","year":"2016","unstructured":"Menzella F, Lusuardi M, Galeone C, Facciolongo N, Zucchi L. The clinical profile of benralizumab in the management of severe eosinophilic asthma. Ther Adv Respir Dis. 2016, 10:534-548. 10.1177\/1753465816667659","journal-title":"Ther Adv Respir Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S155307","article-title":"Benralizumab in the treatment of severe asthma: design, development and potential place in therapy","volume":"12","author":"Pelaia C","year":"2018","unstructured":"Pelaia C, Vatrella A, Bruni A, Terracciano R, Pelaia G. Benralizumab in the treatment of severe asthma: design, development and potential place in therapy. Drug Des Devel Ther. 2018, 12:619-628. 10.2147\/DDDT.S155307","journal-title":"Drug Des Devel Ther"},{"key":"ref11","unstructured":"Fasenra prices, coupons & patient assistance programs. https.\/\/www.drugs.com\/price-guide\/fasenra."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/62935-plausible-role-of-asthma-biological-modifiers-in-the-treatment-of-eosinophilic-esophagitis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:32:45Z","timestamp":1707507165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/62935-plausible-role-of-asthma-biological-modifiers-in-the-treatment-of-eosinophilic-esophagitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,18]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.16460","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,18]]}}}